Dr. Theresa Mullin to Join CDER
Theresa Mullin, PhD, will join CDER on September 24, 2007, as the associate director for analysis and strategic initiatives.
Theresa Mullin, PhD, will join CDER on September 24, 2007, as the associate director for analysis and strategic initiatives. As associate director, she will lead CDER’s long-range planning and strategic modernization initiatives.
Mullin previously worked as the assistant commissioner for planning and as director of the office of planning in the office of the commissioner. As chief planner, she led the development of the FDA’s strategic action plans and performance plans that were incorporated into agency budget requests. Mullin played a role in establishing the FDA Bioinformatics Board and provided early support for the FDA critical path initiative. Prior to her work at the FDA, Mullin worked as a principal scientist with the Decision Science Consortium, and as senior manager with the Lewin Group.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
FDA Reopens Comment Period on HCP Immunogenicity Risk of Follow-on Recombinant Peptides
January 2nd 2025FDA is reopening the comment period for the Federal Register Notice, “Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-on Recombinant Peptide Products: Establishment of a Public Docket: Request for Information and Comments”, until March 3, 2025.
